Deepwise Debuts MetAI X Multimodal Medical Imaging Platform at CCR2025, Paving the Way for AI-Driven Radiology Innovation

From November 13 to 16, 2025, the 32nd Chinese Congress of Radiology (CCR2025), organized by the Chinese Medical Association, grandly convened at the Changsha International Conference Center. As the annual premier event in China’s medical imaging field, the congress centered on academic exchange, bringing together top global radiology experts, scholars, and industry leaders to explore frontier advancements and technological innovations, achieving unprecedented scale. DeepWise, a pioneer in the medical AI industry, made a prominent debut with its next-generation multimodal intelligent imaging large model platform—Deepwise MetAI X. Featuring a revolutionary “dual-bus” architecture, this product integrates multimodal data from radiology, ultrasound, endoscopy, and more. Equipped with dual AI engines for “imaging + text,” it constructs a hospital-wide imaging ecosystem hub covering the entire workflow of “screening, diagnosis, treatment, management, education, and research.” This launch fully demonstrated DeepWise’s robust capability in empowering clinical practice with AI, injecting new momentum into intelligent healthcare at the congress.

Co-hosted by the Chinese Medical Association and its Branch of Radiology, and organized by the Hunan Medical Association and its Professional Committee on Radiology, this conference is themed “Imaging-Led Collaboration, Intelligence-Driven Future.” It aims to provide a high-level academic exchange platform for medical practitioners, researchers, educators, and graduate students in the field of radiology.

DeepWise showcased its core product, the Deepwise MetAI X Multimodal Intelligent Imaging Large Model Capability Platform, at the conference. This participation serves as a profound response to the theme of collaborative innovation and represents a significant practice in implementing DeepWise’s technological solutions. On one hand, by presenting end-to-end solutions for multimodal imaging AI, DeepWise deeply integrates urgent clinical needs with technological innovation, providing the industry with practical, replicable models for intelligent diagnosis and treatment. On the other hand, leveraging this premier academic platform, DeepWise engages with global experts and industry peers to explore the integration pathways of AI and radiology, promoting the co-development of technical standards and synergistic industry ecosystems. Through continuous innovative achievements, DeepWise injects new momentum into the intelligent and precise development of radiology, facilitating the transition of medical AI from technological exploration to large-scale clinical application.

DeepWise MetAI X, the multimodal intelligent imaging large model capability platform, showcased its full product lineup at the booth. The Feiying Intelligent Reconstruction and Printing Platform and the Ruiying One-Stop AI-Assisted Diagnosis, Assessment, Disease-Specific Data, Research, and Teaching Platform comprehensively demonstrated the clinical application value of these products across diverse scenarios. Built on a revolutionary “dual-bus” architecture for medical imaging and deconstructed data, the platform fully integrates multimodal data from radiology, ultrasound, endoscopy, nuclear medicine, and pathology, striving to create a hospital-wide imaging ecosystem hub and redefine the new boundaries of intelligent medical imaging. It also provides capability platforms for large models such as DeepSeek and healthcare-specific vertical large models, truly achieving AI-driven digital intelligence across entire workflows and all scenarios.

At this exhibition, DeepWise established an experience zone for its Multimodal Smart Imaging Integrated Platform (AI-PACS) in the core area of its booth. Featuring the industry-exclusive “AI-Integrated Full-Process Workflow,” this platform serves as the core vehicle for deeply empowering medical imaging across all scenarios with AI technology. Centered on “full-process intelligent integration,” the platform highly embeds and integrates various needs and applications involved in physicians’ workflows, such as intelligent reconstruction of medical images, computer-aided diagnosis, automated generation of structured reports, and multimodal data research. It constructs a revolutionary “dual-bus” architecture for medical imaging and deconstructed data, boasting high-performance computing capabilities with high concurrency. The platform intelligently manages departmental GPUs and dynamically allocates computing resources in real time, building a one-stop new intelligent imaging hub for medical institutions at all levels. This enables physicians to freely interact and share data across all stages of “screening, diagnosis, treatment, management, education, and research,” thereby optimizing overall workflows and providing comprehensive support throughout the entire process and across all scenarios.

DeepWise remains steadfast in its commitment to innovation. In addition to the Deepwise MetAI X intelligent medical imaging large model capability platform showcased at this event, DeepWise launched the Deepwise TrioData X multimodal medical data large model capability platform in August 2025. Centered on the core mission of “reconstructing the value of medical data,” the company has creatively established a full-stack closed loop encompassing “data governance – capability innovation – scenario implementation.” This approach transforms vast amounts of multi-source data into a high-quality, trustworthy data asset hub, empowering healthcare institutions at all levels across clinical practice, scientific research, management, and AI innovation capabilities. To date, DeepWise has led or participated in 13 major special projects funded by the Ministry of Science and Technology of China, 16 projects supported by the National Natural Science Foundation of China, and over 30 key provincial and municipal research initiatives. The company has accumulated publications with a total impact factor of nearly 1,800 and has been honored with the Second Prize of the National Science and Technology Progress Award, as well as multiple provincial-level Science and Technology Progress Awards in Shandong, Henan, Zhejiang, Chongqing, and other regions. Driven by sustained investment in scientific research and the efficient translation of achievements into practical applications, products such as Deepwise MetAI X and Deepwise TrioData X consistently remain at the technological forefront, fully demonstrating DeepWise’s profound expertise and industry-leading position in the field of medical AI.

CCR2025 is a highly influential core platform in the industry. At this event, DeepWise comprehensively showcased the technological leadership of its core products, including the Deepwise MetAI X intelligent imaging large model capability platform, as well as its clinical translation achievements in fields such as medical imaging and data governance, allowing industry partners to directly perceive the practical power of AI-empowered healthcare. In the future, DeepWise will remain committed to its original mission of “empowering healthcare with AI to safeguard public health,” continuing to deepen R&D in core medical AI technologies and their clinical translation and application. On one hand, it will focus on key areas such as medical imaging and medical data governance, continuously iterating and upgrading its product portfolio, strengthening core technical advantages in multimodal fusion and large model implementation, and launching intelligent solutions that better align with clinical workflows and meet the needs of medical institutions at various levels. On the other hand, it will deepen cooperation with top domestic and international universities, research institutions, and benchmark hospitals to jointly build an ecosystem for technological innovation and a system of industry standards, promoting the transition of medical AI from isolated applications to full-process, hospital-wide scaled implementation, thereby injecting sustained momentum into the healthcare sector.